Paracetamol (Acetaminophen) Dosage Calculator

Pharmacology and Mechanism of Action

Paracetamol (acetaminophen in North America) is one of the world's most widely used analgesic and antipyretic medications, yet its precise mechanism of action remains incompletely understood. Unlike NSAIDs, paracetamol has minimal anti-inflammatory effects and doesn't inhibit peripheral cyclooxygenase (COX) enzymes significantly. Its primary action occurs centrally in the brain, where it inhibits COX-2 selectively, reducing prostaglandin synthesis in the hypothalamus to lower fever setpoint. It also modulates the endocannabinoid system—paracetamol is metabolized to AM404, a compound that activates cannabinoid CB1 receptors and inhibits anandamide reuptake, contributing to analgesia.

Oral paracetamol is absorbed almost completely from the small intestine, with bioavailability around 80-90%. Peak plasma concentrations occur 30-60 minutes after ingestion. The drug distributes evenly throughout most body tissues and crosses the blood-brain barrier readily. Plasma half-life is approximately 2-3 hours in adults with normal hepatic function. Metabolism occurs primarily in the liver via glucuronidation (50-60%), sulfation (25-30%), and CYP450 oxidation (5-10%). The minor CYP2E1 pathway produces the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI), which is normally detoxified by conjugation with glutathione. When glutathione stores deplete during overdose, NAPQI accumulates and causes hepatocellular necrosis.

Paracetamol's efficacy for mild to moderate pain rivals that of NSAIDs for conditions like headache, dental pain, and osteoarthritis. For severe pain, it serves as an adjunct to opioids, with the combination providing synergistic analgesia and allowing lower opioid doses. As an antipyretic, paracetamol reduces fever by approximately 1-2°C within 2-3 hours, though it doesn't affect body temperature in afebrile individuals. Its cardiovascular safety profile is superior to NSAIDs—no increased risk of myocardial infarction, stroke, or heart failure—making it preferred in elderly patients and those with cardiovascular disease. The main limitation is hepatotoxicity risk with overdose or chronic excessive use.

Intravenous paracetamol (available as Ofirmev in the US) provides more rapid analgesia than oral formulations, with onset within 5-10 minutes. IV dosing is 15 mg/kg (up to 1000 mg) every 6 hours, maximum 4 grams daily. It's used perioperatively to reduce opioid requirements and in hospitalized patients unable to take oral medications. Rectal paracetamol suppositories (10-20 mg/kg) are an alternative in children who are vomiting or NPO, though absorption is more variable than oral administration. Extended-release formulations (Tylenol Arthritis, 650 mg twice daily) provide sustained levels for chronic pain but carry overdose risk if patients don't recognize they contain paracetamol and add additional doses.

Dosing Strategies Across the Lifespan

Pediatric paracetamol dosing follows weight-based calculations to avoid underdosing (ineffective treatment) or overdosing (toxicity risk). The standard is 10-15 mg/kg per dose every 4-6 hours, not exceeding 75 mg/kg per day or 4000 mg daily, whichever is lower. For a 10 kg infant, each dose is 100-150 mg; for a 30 kg school-age child, 300-450 mg. Liquid formulations come in two concentrations: infant drops (80 mg/0.8 mL) and children's suspension (160 mg/5 mL). Confusing these concentrations has caused overdoses—always check the label and use the measuring device provided. Suppositories are dosed at 10-20 mg/kg every 4-6 hours rectally.

Neonates and premature infants require modified dosing due to immature hepatic conjugation pathways. Term neonates can receive 10-15 mg/kg every 6-8 hours (longer intervals than older children). Premature infants may need even longer intervals (every 8-12 hours) with doses of 10 mg/kg to avoid accumulation. Continuous IV paracetamol infusions are used in some NICUs for post-surgical pain or patent ductus arteriosus treatment. Therapeutic drug monitoring is sometimes employed in neonates to ensure levels of 10-20 mg/L, providing analgesia while avoiding the 150-200 mg/L range associated with toxicity.

Adult dosing is typically fixed rather than weight-based: 500-1000 mg every 4-6 hours. However, patients under 50 kg should use weight-based dosing (10-15 mg/kg) to avoid relative overdosing. The maximum daily dose of 4000 mg applies to healthy adults under 65 with normal liver function. Many experts now recommend a maximum of 3000 mg daily to provide a safety margin, particularly for chronic use. Patients with chronic alcohol use, malnutrition, or fasting states have depleted glutathione and are more susceptible to toxicity; these individuals should limit intake to 2000 mg daily and consider alternative analgesics like NSAIDs if no contraindications exist.

Geriatric patients (over 65) should observe a maximum of 3000 mg daily due to age-related decline in hepatic function and reduced glutathione reserves. Renal elimination of glucuronide and sulfate metabolites also decreases with age, leading to accumulation with repeated dosing. Cognitive impairment in dementia patients increases risk of accidental overdose from forgetting previous doses or taking multiple paracetamol-containing products simultaneously. Caregivers should manage medications and track doses. Combination products (paracetamol plus opioid, or paracetamol in cold remedies) are particularly hazardous—patients often don't realize they contain paracetamol and add standalone paracetamol, inadvertently exceeding safe limits.

Overdose Recognition, Management, and Prevention

Acute paracetamol overdose is one of the most common poisonings worldwide and the leading cause of acute liver failure in many countries. The toxic dose is approximately 150 mg/kg or 7.5 grams in adults, whichever is lower. In children, 200 mg/kg is considered potentially toxic. The clinical course unfolds in four stages. Stage I (0-24 hours) features nonspecific symptoms: nausea, vomiting, malaise, and pallor. Patients often feel better by 24 hours, creating false reassurance. Stage II (24-72 hours) shows rising transaminases (AST, ALT) and right upper quadrant pain as hepatotoxicity begins. Stage III (72-96 hours) brings peak liver injury with jaundice, coagulopathy (elevated INR/PT), hypoglycemia, and hepatic encephalopathy. Stage IV (>5 days) is either recovery or progression to fulminant hepatic failure requiring transplantation.

The Rumack-Matthew nomogram guides treatment decisions. A paracetamol level drawn 4-24 hours post-ingestion is plotted on the nomogram. Levels above the treatment line (150 mg/L at 4 hours, declining to 30 mg/L at 16 hours) indicate need for N-acetylcysteine (NAC) therapy. NAC replenishes hepatic glutathione, allowing detoxification of NAPQI. The oral protocol is 140 mg/kg loading dose, then 70 mg/kg every 4 hours for 17 doses. The IV protocol (more commonly used due to better tolerability) is 150 mg/kg over 1 hour, then 50 mg/kg over 4 hours, then 100 mg/kg over 16 hours (total 21 hours). Starting NAC within 8 hours post-ingestion prevents hepatotoxicity in nearly 100% of cases; efficacy declines sharply after 24 hours, though NAC is still given even in late presentations.

Chronic paracetamol toxicity from therapeutic overdose (>4 grams daily for several days) presents differently from acute overdose. Patients develop elevated transaminases and hepatotoxicity without the classic overdose history. The nomogram doesn't apply; treatment is based on clinical suspicion and laboratory markers. Risk factors include chronic alcohol use, malnutrition, concurrent use of CYP2E1 inducers (phenytoin, rifampin, isoniazid), and fasting states. Intentional overdoses in suicide attempts often involve co-ingestion of alcohol or other drugs, complicating management. Activated charcoal (50 grams) reduces paracetamol absorption if given within 1-2 hours of ingestion, though it's less useful for delayed presentations.

Prevention requires patient education and product labeling improvements. Many over-the-counter products contain paracetamol: cold remedies (Theraflu, DayQuil), sleep aids (Tylenol PM), menstrual products (Pamprin), and combination analgesics (Excedrin). Patients must read labels and total their daily paracetamol intake across all products. The FDA now requires prescription combinations (Percocet, Vicodin) to contain no more than 325 mg paracetamol per tablet, reducing overdose risk from opioid combination products. Some countries have restricted package sizes to 32 tablets per container, which has reduced overdose deaths. Pharmacists should counsel patients purchasing paracetamol about safe dosing limits, avoiding alcohol, and recognizing early symptoms of liver injury (jaundice, dark urine, severe fatigue, right upper quadrant pain) that warrant immediate medical evaluation.